ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
IP
Institut Paoli-Calmettes at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Institut Paoli-Calmettes takes part in 10 sessions at ESMO 2026 in Madrid. Its sessions span treatment choices and precision care across cancers. They examine prostate cancer treatment guided by PSMA, treatment decisions for CLDN18.2-positive stomach cancer, and circulating tumour DNA in breast cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
IP Institut Paoli-Calmettes Marseille, France | |
Comprehensive cancer centre in Marseille, France, part of the Unicancer network of French cancer centres. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Circulating tumour DNA dynamics predicts treatment efficacy in metastatic triple-negative androgen receptor-positive breast cancer enrolled in the START phase II trial Breast cancerSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Satellite Fri Oct 23 18:25–18:35 Unboxing first-line treatment choice Gastrointestinal cancers Satellite Fri Oct 23 18:35–18:45 Selecting your piece: CLDN18.2 targeted therapies Gastrointestinal cancers Satellite Fri Oct 23 18:55–19:10 The emerging picture: Precision medicine in clinical decision-making Gastrointestinal cancers Satellite Fri Oct 23 19:20–19:40 The complete picture: Enhancing patient care Gastrointestinal cancers Poster Sat Oct 24 12:00–12:45 Satellite Sat Oct 24 13:00–14:30 Novartis - PSMA-targeted RLT in Prostate Cancer: Present and future Genitourinary cancers Satellite Sat Oct 24 13:00–13:05 Welcome, introduction, and objectives for the session Genitourinary cancers Satellite Sat Oct 24 13:05–13:15 PSMA RLT in prostate cancer: What the guidelines say in 2026 Genitourinary cancers Satellite Sat Oct 24 14:17–14:27 Future landscape in Prostate Cance Genitourinary cancers Poster Sun Oct 25 12:00–12:45 IMHOTEP phase II trial: 3-year follow-up Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 13:00–13:18 Talk Mon Oct 26 10:15–10:20 Presentation of case/condition Genitourinary cancers Talk Mon Oct 26 10:40–11:00 What to do with the primary in extreme responders Genitourinary cancers Abstract Mon Oct 26 16:54–17:06 LBA10 - MOIO: Interim analyses of a phase III randomized non inferiority trial assessing reduced frequency immune checkpoint inhibitors in responding patients with advanced/metastatic cancer Gynaecological cancersSarcoma, CNS, head & neck and rare cancers |
Find decision makers at Institut Paoli-Calmettes
Tell us what you sell and we’ll find the people at Institut Paoli-Calmettes most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction